Table 5.
Survival outcomes of the assessable patients according to the different risk groups.
| Models and risk groups | Patient, n | Median OS | 5-Year OS rates | HR (95%CI) | P value |
|---|---|---|---|---|---|
| MSKCC score | 0.004 | ||||
| Low-risk | 44 (23%) | 44 | 37.5% | – | |
| Intermediate-risk | 111 (57%) | 39 | 33.7% | 1.461 (0.838,2.545) | |
| High-risk | 38 (20%) | 17 | 14.1% | 2.687 (1.446,4.991) | |
| LLR | 0.016 | ||||
| Low (≤166.8) | 89 (54%) | 50 | 43.4% | – | |
| High (>166.8) | 77 (46%) | 32 | 25.4% | 1.710 (1.105,2.646) | |
| Low-intermediate MSKCC risk | 0.007 | ||||
| LLR ≤ 166.8 | 70 (53%) | 74 | 56.1% | – | |
| LLR > 166.8 | 63 (47%) | 33 | 26.6% | 2.082 (1.221,3.552) |
MSKCC, Memorial Sloan Kettering Cancer Center; OS, overall survival; LLR, lactate dehydrogenase-to-lymphocyte ratio; the median overall survival time is calculated in months.